ACP-105
目录号 : GC31738ACP-105 is an orally available and potent selective androgen receptor modulator (SARM) with pEC50 of 9.0 and 9.4 for AR wild type and AR mutation T877A, respectively.
Cas No.:899821-23-9
Sample solution is provided at 25 µL, 10mM.
ACP-105 is an orally available and potent selective androgen receptor modulator (SARM) with pEC50 of 9.0 and 9.4 for AR wild type and AR mutation T877A, respectively.
[1] Nathalie Schlienger, et al. J Med Chem. 2009 Nov 26;52(22):7186-91. [2] Catherine Dayger, et al. Brain Res. 2011 Mar 24;1381:134-40.
Animal experiment: | Mice[2]Two-month-old C56Bl/6J female mice are kept on a 12:12 hr light-dark schedule (lights on at 6 AM) with lab chow and water given ad libitum. Following i.p. anesthesia (ketamine, 80 mg/kg and xylazine, 20 mg/kg), mice are sham-irradiated (n=7 sham vehicle-treated mice and n=7 ACP-105-treated mice) or irradiated (n=8 vehicle-treated mice and n=7 ACP-105-treated mice) using a dose of 10 Gy in a Mark 1 Cesium Irradiator. Twenty-four hours following irradiation, the mice are implanted with Alzet minipumps filled with ACP-105 at 1 mg/kg/day or 1.09 mg/200 μL in 10% Tween in saline or vehicle. Behavioral testing starts two weeks after irradiation. Mice receives three trials per day for three subsequent days. Mice are tested for fear conditioning in week 2. During contextual fear conditioning, mice learn to associate the environmental context with a mild foot shock. Contextual conditioned fear is assessed during the first 3 minutes of the contextual test trial when freezing behavior is most robust. Cued conditioned fear is assessed during the presentation of the tone (the last 3 minutes of the trial)[2]. |
References: [1]. Schlienger N, et al. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem. 2009 Nov 26;52(22):7186-91. |
Cas No. | 899821-23-9 | SDF | |
Canonical SMILES | N#CC1=CC=C(N2[C@@H]3C[C@](O)(C)C[C@H]2CC3)C(C)=C1Cl | ||
分子式 | C16H19ClN2O | 分子量 | 290.79 |
溶解度 | DMSO : ≥ 103 mg/mL (354.21 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.4389 mL | 17.1945 mL | 34.3891 mL |
5 mM | 0.6878 mL | 3.4389 mL | 6.8778 mL |
10 mM | 0.3439 mL | 1.7195 mL | 3.4389 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet